Work

Computational identification and in vitro evaluation of astragaloside II as an inhibitor of dengue virus NS1-induced endothelial hyperpermeability

Year: 2026
Type: preprint
Abstract: Background Dengue is a mosquito-borne viral disease in which severe cases are marked by leakage of plasma from blood vessels. The secreted nonstructural protein 1 (NS1) of dengue virus damages the endothelial barrier and is a drug target, but no approved antiviral exists. We aimed to identify compounds that target NS1 and to test whether the selected compound, astragaloside II (ASII), counteracts NS1-induced endothelial hyperpermeability. Methodology/Principal findings We built a deep learning model that predicts compound– target binding from chemical fingerprints and protein sequences, and used it to prescreen 177 natural compounds against NS1 of the four dengue virus serotypes. The model outperformed the DeepConv-DTI baseline in recall and F1-score on a BindingDB holdout set and on two independent test sets. ASII was predicted to bind NS1 and was docked onto the NS1 dimer. In human microvascular endothelial cells (HMEC-1), NS1 reduced the relative trans-endothelial electrical resistance to 0.56 (P < 0.001), whereas ASII at 10–30 µg/mL kept resistance close to control levels without detectable cytotoxicity. ASII did not reduce NS1 internalization. In a competitive enzyme-linked immunosorbent assay, ASII inhibited NS1 binding to heparan sulfate in a dose-dependent manner (half-maximal inhibitory concentration 51.12 µg/mL; 95% confidence interval 47.91–56.24 µg/mL), although inhibition at the protective doses was only 8–26%. Conclusions/Significance ASII is a candidate for further study as a modulator of NS1-induced endothelial hyperpermeability. Its mechanism remains unresolved and requires further study. Direct binding to NS1, activity in infected cells and effects in other endothelial models were not tested here, and the computational predictions require experimental confirmation. Author summary Dengue is a viral disease spread by mosquitoes that infects hundreds of millions of people each year. In severe cases, fluid leaks out of the smallest blood vessels, which can cause shock and death. No approved medicine treats the infection itself. A viral protein called NS1, which infected cells release into the blood, helps cause this leakage by damaging the lining of the blood vessels. We therefore looked for a compound that could block the harmful effects of NS1. We trained a computer program to predict which chemicals are likely to stick to a given protein, and we used it to rank 177 natural compounds. We chose one of the best-ranked compounds, astragaloside II, which comes from a plant used in traditional Chinese medicine. In cultures of blood vessel cells, NS1 weakened the cell layer, and astragaloside II prevented this damage without harming the cells. The compound also reduced the binding of NS1 to a sugar-like molecule on cell surfaces, but only weakly at the doses that protected the cells. We did not test it in infected cells or animals, so we regard it as a lead for further work, not as a treatment.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7233919527
Cites: 33
Cited by:
Related to: 10